SCHEMBL5361674

SCHEMBL5361674

O=c1c(-c2ncc(Cc3ccccc3)o2)cn(Cc2ccc(Cl)cc2)c2ccc(O)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
PLA2G2A P14555 1/20 0.43
ESR1 P03372 2/20 0.41
USP10 Q14694 1/20 0.41
ENPP2 Q13822 1/20 0.40
ESR2 Q92731 1/20 0.39
CNR2 P34972 1/20 0.39
LMNA P02545 4/20 0.39
HTT P42858 2/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
ALDH1A1 P00352 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5346945 0.86 LMNA (0.53) SMN1; SMN2PLA2G2AUSP10LMNAALDH1A1
SCHEMBL14351241 0.80 LTA4H (0.46) PPARGPPARDPPARAALDH1A1KDM4E
SCHEMBL5358366 0.79 PPARG (0.43) PPARGPPARDPPARA
SCHEMBL5464650 0.79 SMN1; SMN2 (0.45) SMN1; SMN2RXFP1PLA2G2AESR1USP10
SCHEMBL5322818 0.68 XDH (0.52) SMN1; SMN2PLA2G2AHTTALDH1A1PDE4A
SCHEMBL2003091 0.67 PLA2G2A (0.64) PLA2G2ACNR2LMNAHTTALDH1A1
SCHEMBL2944827 0.67 ENPP2 (0.48) PLA2G2AESR1ENPP2LMNAPDE4A
SCHEMBL5544822 0.66 LMNA (0.73) SMN1; SMN2RXFP1LMNAALDH1A1
SCHEMBL5353654 0.66 LMNA (0.55) SMN1; SMN2PLA2G2AUSP10LMNAALDH1A1
SCHEMBL11948628 0.65 LMNA (0.71) LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
WO-2007130499-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-11-15 WO disclosed
US-7279580-B2 Imidazo-pyridine derivatives as ligands for GABA receptors MERCK SHARP & DOHME LIMITED (GB) 2007-10-09 US disclosed
US-20050165048-A1 Imidazo-pyridine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2005-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165048-A1 Imidazo-pyridine derivatives as ligands for gaba receptors GABRA3, GABRA2, GABRA5 SMN1; SMN2 2179/4885RXFP1 1479/4885PLA2G2A 4558/4885
US-20070287699-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 SMN1; SMN2 2454/4885RXFP1 4526/4885PLA2G2A 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.